Powered by

-Promore Pharma receives approval for Phase III study with PXL01 in India

Nov 20, 2018 - ENP Newswire

STOCKHOLM - Promore Pharma AB, a Swedish biopharmaceutical developer of therapeutic peptides, today announced that the Drug Controller General in India (DCGI) has approved the company's application to start a clinical Phase III study with PXL01 to prevent post-surgical adhesions after tendon repair surgery.

The Indian medical authority, Drug Controller General in India has approved the company's application for a clinical Phase III study with PXL01. The approval is for a double-blind clini...